4888 STELLA PHARMA CORPORATION - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4888

TSE Growth

STELLA PHARMA CORPORATION

251

JPY

-1

(-0.40%)

Dec 5, 3:30 pm JST

1.62

USD

Dec 5, 1:30 am EST

Result

PTS

outside of trading hours

250.5

Dec 5, 11:29 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	100	-741	-764	-767	-27.3	0	May 10, 2022	J-GAAP
Mar, 2023	229	-806	-775	-778	-27.0	0	May 9, 2023	J-GAAP
Mar, 2024	269	-760	-760	-763	-24.7	0	May 10, 2024	J-GAAP
Mar, 2025	961	-90	-137	-140	-4.2	0	May 9, 2025	J-GAAP
Mar, 2026 Guidance	377	-922	-908	-911	-26.8	0	Oct 14, 2025	J-GAAP
YoY	-60.8%	-924.4%	-562.8%	-550.7%	-534.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	Apr 22, 2021	205	-688	-658	-661	0	J-GAAP
Results	May 10, 2021	205	-680	-656	-659	0	J-GAAP
Mar, 2022	May 10, 2021	Available in future release
	Nov 8, 2021
	May 6, 2022
Results	May 10, 2022
Mar, 2023	May 10, 2022
	Feb 10, 2023
Results	May 9, 2023
Mar, 2024	May 9, 2023
	Feb 13, 2024
Results	May 10, 2024
Mar, 2025	May 10, 2024
Results	May 9, 2025
Mar, 2026	May 9, 2025	1,007	-348	-345	-348	0	J-GAAP
	Oct 14, 2025	377	-922	-908	-911	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2015	417	－	Available in future release
Dec, 2016	144	-65.5
Mar, 2018 Changed	0	－
Mar, 2019	0	－
Mar, 2020	0	－
Mar, 2021	205	－
Mar, 2022	100	-51.2
Mar, 2023	229	+129.0
Mar, 2024	269	+17.5
Mar, 2025	961	+257.2
Mar, 2026 Guidance	377	-60.8	-922	-924.4	-908	-562.8	-26.8	-538.1

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	269	-760	-283	-29.85	-18.73	0.07	-24.7
Mar, 2025	961	-90	-9.4	-5.02	-3.03	0.21	-4.2
Mar, 2026 Guidance	377	-922	-245	-31.42	-18.50	0.08	-26.8

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	961	-90	29	19	97.1
Fiscal Year	Mar, 2025	Mar, 2025	Dec, 2015	Dec, 2015	Dec, 2015

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	137	-440	-433	-434	-15.0	0	May 9, 2023	J-GAAP
Oct - Mar, 2023	116	-459	-457	-458	-14.8	0	May 10, 2024	J-GAAP
Oct - Mar, 2024	792	179	130	128	3.9	0	May 9, 2025	J-GAAP
Oct - Mar, 2025 Guidance	177	-624	-602	-604	-17.8	0	Nov 13, 2025	J-GAAP
YoY	-77.7%	－	－	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	-806	-856	-827	-29	291	2,669	61.65	J-GAAP
Mar, 2024	-760	-885	-876	-9	228	2,012	52.67	J-GAAP
Mar, 2025	-90	427	140	287	721	3,161	58.35	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	153	-301	-303	-305	-10.0	ー	Nov 9, 2023	J-GAAP
Apr - Sep, 2024	169	-269	-267	-268	-8.2	ー	Nov 8, 2024	J-GAAP
Apr - Sep, 2025	200	-298	-306	-307	-9.1	ー	Nov 13, 2025	J-GAAP
YoY	+18.3%	-10.8%	-14.6%	-14.6%	-10.2%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	47	-165	-163	-164	-5.3	-351.1	Feb 13, 2024	J-GAAP
Jan - Mar, 2024	69	-294	-294	-294	-9.5	-426.1	May 10, 2024	J-GAAP
Apr - Jun, 2024	61	-166	-161	-161	-5.1	-272.1	Aug 7, 2024	J-GAAP
Jul - Sep, 2024	108	-103	-106	-107	-3.3	-95.4	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	85	-106	-104	-105	-3.2	-124.7	Feb 12, 2025	J-GAAP
Jan - Mar, 2025	707	285	234	233	7.0	40.3	May 9, 2025	J-GAAP
Apr - Jun, 2025	92	-151	-155	-156	-4.6	-164.1	Aug 7, 2025	J-GAAP
Jul - Sep, 2025	108	-147	-151	-151	-4.5	-136.1	Nov 13, 2025	J-GAAP
YoY	0.0%	-42.7%	-42.5%	-41.1%	-35.7%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	50	－	Available in future release
Apr - Jun, 2021	7	－
Jul - Sep, 2021	62	－
Oct - Dec, 2021	15	－
Jan - Mar, 2022	16	-68.0
Apr - Jun, 2022	46	+557.1
Jul - Sep, 2022	46	-25.8
Oct - Dec, 2022	83	+453.3
Jan - Mar, 2023	54	+237.5
Apr - Jun, 2023	61	+32.6
Jul - Sep, 2023	92	+100.0
Oct - Dec, 2023	47	-43.4
Jan - Mar, 2024	69	+27.8
Apr - Jun, 2024	61	0.0
Jul - Sep, 2024	108	+17.4
Oct - Dec, 2024	85	+80.9
Jan - Mar, 2025	707	+924.6
Apr - Jun, 2025	92	+50.8
Jul - Sep, 2025	108	0.0	-147	-42.7	-151	-42.5	-4.5	-36.4

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	707	285	234	233	7.0
Fiscal Year	Mar, 2025	Mar, 2025	Mar, 2025	Mar, 2025	Mar, 2025

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	91.51	63.3	4,329	2,742	-778	0.40	May 9, 2023	J-GAAP
Mar, 2024	75.90	62.0	3,820	2,370	-763	0.39	May 10, 2024	J-GAAP
Mar, 2025	94.26	59.2	5,417	3,207	-140	0.24	May 9, 2025	J-GAAP
Apr - Sep, 2025	ー	58.9	4,924	2,899	-307	0.24	Nov 13, 2025	J-GAAP

STELLA PHARMA CORPORATION(4888) Financial Results